Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use

Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use Drugs Ther Perspect (2018) 34:288 https://doi.org/10.1007/s40267-018-0526-y CORRECTION Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use 1 1 Kate McKeage Katherine A. Lyseng-Williamson Published online: 6 June 2018 Springer International Publishing AG, part of Springer Nature 2018 Correction to: Drugs Ther Perspect https://doi.org/10.1007/s40267-018-0522-2 The Acknowledgements section on the last page should read: ‘‘The manuscript was reviewed by: P.F. Ambros, Chil- dren’s Cancer Research Institute, St. Anna Kinderkrebs- forschung, Vienna, Austria; F.H. Felix, Pediatric Cancer Center, Hospital Infantil Albert Sabin, Fortaleza, Brazil; R. Kebudi, Division of Pediatric Hematology-Oncology, Cerrahpas ¸ a Medical Faculty & Oncology Institute, Istan- bul, Turkey; H.B. Lindsay, Pediatric Hematology/Oncol- ogy, Baylor College of Medicine, Houston, TX, USA; J. Morales, Pharmacy Department, Hospital Dr Luis Calvo Mackenna, Santiago, Chile. During the peer review pro- cess, EUSA Pharma (UK) Limited, the marketing-autho- rization holder of dinutuximab beta, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit. The original article has been corrected. The original article can be found online at https://doi.org/10.1007/ s40267-018-0522-2. & Katherine A. Lyseng-Williamson dtp@adis.com Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs & Therapy Perspectives Springer Journals

Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/correction-to-dinutuximab-beta-in-high-risk-neuroblastoma-a-profile-of-CYAjtOzBFY
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Pharmacy; Pharmacy; Pharmacotherapy
ISSN
1172-0360
eISSN
1179-1977
D.O.I.
10.1007/s40267-018-0526-y
Publisher site
See Article on Publisher Site

Abstract

Drugs Ther Perspect (2018) 34:288 https://doi.org/10.1007/s40267-018-0526-y CORRECTION Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use 1 1 Kate McKeage Katherine A. Lyseng-Williamson Published online: 6 June 2018 Springer International Publishing AG, part of Springer Nature 2018 Correction to: Drugs Ther Perspect https://doi.org/10.1007/s40267-018-0522-2 The Acknowledgements section on the last page should read: ‘‘The manuscript was reviewed by: P.F. Ambros, Chil- dren’s Cancer Research Institute, St. Anna Kinderkrebs- forschung, Vienna, Austria; F.H. Felix, Pediatric Cancer Center, Hospital Infantil Albert Sabin, Fortaleza, Brazil; R. Kebudi, Division of Pediatric Hematology-Oncology, Cerrahpas ¸ a Medical Faculty & Oncology Institute, Istan- bul, Turkey; H.B. Lindsay, Pediatric Hematology/Oncol- ogy, Baylor College of Medicine, Houston, TX, USA; J. Morales, Pharmacy Department, Hospital Dr Luis Calvo Mackenna, Santiago, Chile. During the peer review pro- cess, EUSA Pharma (UK) Limited, the marketing-autho- rization holder of dinutuximab beta, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit. The original article has been corrected. The original article can be found online at https://doi.org/10.1007/ s40267-018-0522-2. & Katherine A. Lyseng-Williamson dtp@adis.com Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand

Journal

Drugs & Therapy PerspectivesSpringer Journals

Published: Jun 6, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off